Bloodstream infections in patients with solid tumors

Gudiol, Carlota; Aguado, José María; Carratalà, Jordi

doi:10.1080/21505594.2016.1141161

Cited by 82 publications

(98 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, even when patients with NHL were excluded, the SMRs remained significantly elevated among all other AYAs with cancer combined. Other cancer types with noticeably high SMRs for infectious diseases included leukemia and HL, consistent with the potential for hematologic malignancies to directly compromise bone marrow and with a greater likelihood of exposure to immunosuppressive chemotherapies and HSCT in these patients than in those with nonhematologic cancers . However, with the exception of melanoma and thyroid cancer, SMRs for infectious diseases were also significantly elevated for AYAs with all other cancer types we examined, likely reflecting a combination of treatment‐related and host‐related risk factors.…”

Section: Discussionsupporting

confidence: 59%

“…Other cancer types with noticeably high SMRs for infectious diseases included leukemia and HL, consistent with the potential for hematologic malignancies to directly compromise bone marrow and with a greater likelihood of exposure to immunosuppressive chemotherapies and HSCT in these patients than in those with nonhematologic cancers. 25,26 However, with the exception of melanoma and thyroid cancer, SMRs for infectious diseases were also significantly elevated for AYAs with all other cancer types we examined, likely reflecting a combination of treatment-related and host-related risk factors. For some cancer types, including hematologic malignancies, CNS tumors, and cervical/ uterine cancers, the increase persisted at ≥20 years postdiagnosis, and further research may be needed to investigate cancer treatment-related and other contributors to the long-term excess risk in these groups.…”

Section: Discussionmentioning

confidence: 85%

See 1 more Smart Citation

Noncancer mortality among adolescents and young adults with cancer

Anderson

Lund

Weaver

et al. 2019

Cancer

View full text Add to dashboard Cite

Background Relative to the general population, cancer patients and survivors may have an elevated risk of mortality from noncancer causes, such as cardiovascular disease and infections, but few studies have examined rates of noncancer mortality among patients diagnosed as adolescents and young adults (AYAs) (ages 15‐39 years). Methods The Surveillance, Epidemiology, and End Results database was used to identify AYA patients who were diagnosed with a first malignant cancer between 1973 and 2015. Rates of mortality from noncancer causes among AYAs with cancer were compared with those in the general US population using standardized mortality ratios (SMRs), adjusted for age, sex, race, and calendar year. Results Among 235,541 AYAs with cancer, a total of 12,948 deaths from noncancer causes occurred over 3.1 million total person‐years of follow‐up. Overall, noncancer mortality was significantly increased among AYAs with cancer relative to the general population (SMR, 1.84; 95% CI, 1.80‐1.87). SMRs were particularly elevated for infectious diseases (SMR, 5.13; 95% CI, 4.95‐5.32), cardiovascular disease (SMR, 1.55; 95% CI, 1.50‐1.60), and renal diseases (SMR, 2.40; 95% CI, 2.12‐2.71). These associations persisted for more than 20 years after cancer diagnosis. Cancer types associated with the highest SMRs for all noncancer mortality included leukemias (SMR, 5.26), Hodgkin lymphoma (SMR, 3.12), non‐Hodgkin lymphoma (SMR, 6.33), central nervous system tumors (SMR, 3.38), head and neck cancers (SMR, 2.09), and cervical/uterine cancers (SMR, 2.03). Conclusions AYAs with cancer have an elevated burden of mortality from noncancer causes that persists many years after cancer diagnosis, highlighting the importance of comprehensive, long‐term follow‐up care for noncancer conditions throughout survivorship.

show abstract

Section: Discussionsupporting

confidence: 59%

Section: Discussionmentioning

confidence: 85%

Noncancer mortality among adolescents and young adults with cancer

Anderson

Lund

Weaver

et al. 2019

Cancer

View full text Add to dashboard Cite

show abstract

“…The cause and the physiopathology of the septic complications may be debated. There are authors who consider the primary tumour or the metastases as source of the infection [7]. We believe that the infection results of the retention of the physiologic secretion.…”

Section: Discussionmentioning

confidence: 98%

“…The most frequent sites of sepsis are the biliary, the urinary and the respiratory tracts [7]. Three cases are presented in order to illustrate favourable evolution of cholangio-, uro-, and bronchogenic-sepsis in cancer patients with poor prognosis.…”

Section: Introductionmentioning

confidence: 99%

Non-Neutropenic Sepsis in Cancer Patients: The Luminal Obstruction Syndrome

Kullmann¹,

Füzi²,

Pintér³

2019

JCT

View full text Add to dashboard Cite

Background: Neutropenic sepsis is a frequent complication of cytotoxic chemotherapy delivered for cancer patients. Its management is well determined by clinical guidelines. Non-neutropenic sepsis is another potential complication in cancer patients. Its management is less established in the medical literature. Materials and Methods: Three cases are presented to illustrate favourable evolution of non-neutropenic biliary-, uro-and bronchogenic-sepsis in cancer patients with poor prognosis. Results: All three patients had a survival over six months after the management of the septic complication. Two of them received subsequent systemic anticancer treatment. Conclusions: Survival benefit offered by the management of cancer-related non-neutropenic sepsis may be comparable to the benefit obtained by systemic anticancer treatments. Cost-effectiveness of sepsis management may be better than that of anticancer treatments.

show abstract

“…Cancer patients are more susceptible to severe infection, including those caused by ESBL-PE as these patients can be immunocompromised due to malnutrition, invasive procedures, surgery, chemotherapy, radiation, and some new treatment modalities [3]. As a result, these infections became a significant therapeutic challenge for clinicians due to limited treatment strategy and are associated with delayed initiation of adequate treatment for malignancy, prolonged hospitalization, poor prognosis, increased health care costs, and high case-fatality rate [4,5].…”

Section: Doimentioning

confidence: 99%

Clinical characteristics, antibiotic-resistant patterns and prognostic factors in cancer patients with nosocomial infections caused by extended-spectrum beta-lactamase-producing Escherichia coli: a retrospective study from 2013 to 2019

Jiang¹,

Shi²,

Liu³

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: Nosocomial infections due to Extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-PE) is increasing worldwide. This study aimed to describe the clinical characteristics, antibiotic-resistant patterns, and prognostic factors associated with nosocomial infections caused by ESBL-PE in cancer patients. Methods: This retrospectively analyzed patients with nosocomial infections caused by E. coli from August 2013 to May 2019 and was conducted to investigate the risk factors, clinical features, outcomes, and antibiotic-resistant patterns of these infections. Results: Of the 1008 nosocomial infection episodes, 265 patients suffered from infections with E. coli, and 155 episodes were caused by ESBL-PE. A multivariate analysis showed that the length of antibiotics treatment more than 6.93 days was an independent risk factor for nosocomial infections in cancer patients caused by ESBL-PE. ECOG performance status score more than 2, presence of respiratory tract infection, septic shock, lymphocytopenia, and hypoproteinemia were independent risk factors for 30-day mortality in cancer patients caused by ESBL-PE. Antimicrobial susceptibility showed that the isolated ESBL-PE were highly resistant to aztreonam and third-generation cephalosporins. Conclusions: The length of antibiotics treatment more than 6.93 days increased the risk ratio for ESBL-PE caused nosocomial infections. However, there was no significant difference in the prognoses of patients with ESBL-PE and non-ESBL-PE caused nosocomial infections. ECOG performance status score more than 2, presence of respiratory tract infection, septic shock, lymphocytopenia, and hypoproteinemia were independent risk factors for 30-day mortality in cancer patients with nosocomial infections caused by E. coli. The isolated ESBL-PE were highly resistant to aztreonam and third-generation cephalosporins.

show abstract

Bloodstream infections in patients with solid tumors

Cited by 82 publications

References 57 publications

Noncancer mortality among adolescents and young adults with cancer

Noncancer mortality among adolescents and young adults with cancer

Non-Neutropenic Sepsis in Cancer Patients: The Luminal Obstruction Syndrome

Clinical characteristics, antibiotic-resistant patterns and prognostic factors in cancer patients with nosocomial infections caused by extended-spectrum beta-lactamase-producing Escherichia coli: a retrospective study from 2013 to 2019

Contact Info

Product

Resources

About